Definitions

1. In transplant patients, the risk of developing a malignant tumor ranges from 4% to 18% and may be 100-fold higher than in the general population.
2. Renal transplant patients are known to have an increased risk of malignancy, predominantly skin cancer and reticulum cell or lymphomatous tumors.
3. Cancer. Transplant patients are at a higher risk of cancer development, because under normal conditions the immune system helps to fight cancer in the body. (Web site)
4. In lung transplant patients, the most significant result was a reduced incidence of chronic rejection. (Web site)

Transplant-Related Complications

1. However, SDS patients may be more susceptible to transplant-related complications than other transplant patients.

Kidney Transplantation

1. From the UNOS datadase, 1.8% of liver transplant patients had kidney transplantation.

Fatal Lymphocytic Choriomeningitis

1. Amman, B. R. 2007. Pet rodents and fatal lymphocytic choriomeningitis in transplant patients. (Web site)

Certain Transplant Patients

1. This option is critically important in patients who are receiving immunosuppressive drugs, as in the case of certain transplant patients.

Kidney Transplant Patients

1. Repopulation of the normal intestinal microflora in kidney transplant patients after kidney transplantation may maintain normal bowel function. (Web site)

Half

1. Almost half of the transplant patients had undergone previous bypass grafting procedures without experiencing improvement in myocardial function. (Web site)

Assessment

1. We offer complete evaluation and assessment for adult end-stage liver disease and transplant patients.

Caution

1. Caution should be given relative to oral treatment for transplant patients for at least the first year posttransplant.

Researchers

1. The researchers also found that bone marrow transplant patients with high levels of elafin were more likely to die of GVHD than people with low levels. (Web site)

Frequency

1. Prior to the widespread use of PCP prophylaxis, the frequency of Pneumocystis infection in lung transplant patients alone was as high as 88%. (Web site)

Developing

1. Thus, these bone marrow transplant patients are developing the same accumulation of ammonia (hyperammonemia) seen in children with urea cycle disorders.

Transplantation

1. The team helps transplant patients and families and living donors throughout the entire process of care before, during, and after transplantation.
2. Most heart transplant patients have a rejection episode soon after transplantation.

Doctors

1. Most liver transplant patients at UCSF are referred to the program by primary care doctors or by a specialist. (Web site)

Immune System

1. The exact features of this gene that may help stoke the immune system in transplant patients are not yet fully clear. (Web site)

Clinical Implications

1. Frequency and clinical implications of increased pulmonary artery pressures in liver transplant patients.

Incidence

1. Incidence of adverse events with HMG-CoA reductase inhibitors in liver transplant patients.

Immune Systems

1. Those at greatest danger include people with AIDS, infants, transplant patients, and others whose immune systems may be compromised.

Higher Risk

1. Those with weakened immune systems, such individuals with HIV, or transplant patients taking immunosuppressant drugs, are also at higher risk. (Web site)

Support Groups

1. The health care provider or social worker can also put the patient in touch with support groups for transplant patients.

Technical Problems

1. Furthermore, other groups recently reported no technical problems with TJLB in transplant patients [ 15, 16].

Last Five Years

1. Researchers found significant and steady improvement in survival over time among liver transplant patients with HCC, particularly in the last five years.

Bone Mass

1. Immunosuppressive therapy in organ transplant patients can lead to reduced bone mass, as can tumors of bone and other sites. (Web site)

Treatment

1. Bone marrow transplant patients usually go to medical centers, or hospitals, that specialize in this treatment. (Web site)

Stem Cell Transplant

1. Transplant patients will undergo a stem cell transplant. (Web site)

Five Years

1. All four of the successfully transplant patients continue to have functioning kidneys two to five years later, the researchers said.

Years

1. More than 80% of liver transplant patients are still alive 5 years after their surgery. (Web site)

Cardiac

1. Three-year safety data in renal and cardiac transplant patients did not reveal any unexpected changes in incidence of malignancy compared to the 1-year data. (Web site)
2. Safety data are summarized below for all active-controlled trials in renal (2 trials), cardiac (1 trial), and hepatic (1 trial) transplant patients.
3. Only physicians experienced in immunosuppressive therapy and management of renal, cardiac or hepatic transplant patients should use CellCept. (Web site)

Risk

1. Doctors have known for decades that the immunosuppressive drugs given to transplant patients increase their risk of developing new cancers.

Renal

1. ATGAM Sterile Solution is indicated for the management of allograft rejection in renal transplant patients. (Web site)
2. Effects of fluvastatin on cardiac events in renal transplant patients: ALERT (Assessment of Lescol in Renal Transplantation) study design and baseline data. (Web site)
3. Treatment of hyperlipidemia in renal transplant patients with gemfibrozil and dietary modification. (Web site)

Hepatitis

1. Studies that addressed management of hepatitis C in liver transplant patients only. (Web site)
2. Retrospective study on the impact of hepatitis C virus infection on kidney transplant patients over 20 years.

Immune Globulin

1. Hepatitis B immune globulin is given to liver transplant patients as part of the transplant procedure, and then for several weeks or months afterward. (Web site)

Prophylaxis

1. Entecavir reduces viral load in liver transplant patients who have failed prophylaxis or treatment for hepatitis B (abstract).

Drugs

1. Drug interaction studies have not been conducted with other drugs that may be commonly administered to renal, cardiac or hepatic transplant patients.
2. Drugs primarily used to destroy cancer cells but also used in bone marrow transplant patients without cancer in order to ensure successful engraftment.

Lovastatin

1. Effects of nicotinic acid and lovastatin in renal transplant patients: a prospective, randomized, open-labeled crossover trial. (Web site)
2. The monitoring of lovastatin drug and metabolite levels may be considered in transplant patients who are treated with immunosuppressives and lovastatin. (Web site)

Study

1. The study confirms the significant improvement seen with pegylated interferon versus standard interferon in transplant patients. (Web site)

Echinacea

1. Although the relevance of this is not clear, liver transplant patients should use echinacea cautiously due to its potential hazards.

Rejection

1. Infection, itself, provokes rejection in kidney transplant patients but this observation has not been proven for liver transplantation (21).
2. Hematologic toxicities are dose-related and may be more severe in renal transplant patients whose homograft is undergoing rejection. (Web site)

Azathioprine

1. Azathioprine and hepatic veno-occlusive disease in renal transplant patients. (Web site)
2. In transplant patients, synergistic toxicity to the kidneys has been observed between TMP-SMX and the immunosuppressive drugs cyclosporin A and azathioprine. (Web site)

Cyclosporine

1. Bone mass and mineral metabolism in liver transplant patients treated with FK506 or cyclosporine A. (Web site)
2. Only physicians experienced in immunosuppressive therapy and management of organ transplant patients should prescribe Sandimmune ® (cyclosporine).
3. A pharmacokinetic interaction between diltiazem and cyclosporine has been observed during studies involving renal and cardiac transplant patients. (Web site)

Polio

1. Transplant patients lose their acquired immunity, for example immunity to childhood diseases such as measles or polio.

Fluconazole

1. Fluconazole is commonly used also for prophylaxis in transplant patients [ 1730, 2453].
2. Transplant Patients (Solid Organs) Fluconazole should be used with caution due to possible interactions with immune suppressive agents.
3. Fluconazole may significantly increase cyclosporine levels in renal transplant patients with or without renal impairment. (Web site)

Patients

1. Immunosuppressants are given to transplant patients to prevent organ rejection or to patients with autoimmune diseases. (Web site)
2. Caecitis affects immunocompromised patients, such as those undergoing chemotherapy, patients with AIDS, kidney transplant patients, or the elderly[ 2]. (Web site)
3. Pneumonia due to Pneumocystis carinii occurs in patients with AIDS and in cancer and organ transplant patients. (Web site)

Transplants

1. In a study of living related pediatric liver transplant patients, biliary complications occurred in 38% of transplants.

Transplant

1. Antiviral agents have not been as effective in transplant patients compared to those who have not had a transplant. (Web site)
2. About half of all heart transplant patients develop coronary artery disease one to five years after the transplant. (Web site)

Immunosuppression

1. Despite improvements in immunosuppression, rejection occurs in 50% of liver transplant patients and may cause significant morbidity.
2. The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients.

Tacrolimus

1. The interaction between antiretroviral agents and tacrolimus in liver and kidney transplant patients. (Web site)

Categories

1. Tacrolimus
2. Medicine > Medical Treatments > Surgery > Transplant
3. Immunosuppression
4. Humans > Health > Diseases > Patients
5. Viral Load
6. Books about "Transplant Patients" in Amazon.com
   

Continue: More Keywords - - - - - - - - - -